Is ABVC BIOPHARMA, INC. (ABVC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.5% / 30% | 1.0% / 30% | 3.5% / 30% | 17.14% / 5% | ✗ NOT HALAL |
| DJIM | 7.5% / 33% | 1.0% / 33% | 3.5% / 33% | 17.14% / 5% | ✗ NOT HALAL |
| MSCI | 32.2% / 33% | 4.2% / 33% | 15.3% / 33% | 17.14% / 5% | ✗ NOT HALAL |
| S&P | 7.5% / 33% | 1.0% / 33% | 3.5% / 33% | 17.14% / 5% | ✗ NOT HALAL |
| FTSE | 32.2% / 33% | 4.2% / 33% | 15.3% / 50% | 17.14% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 375.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -119.5% | |
| Return on Assets (ROA) | -31.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Total Debt | $3M |
| Debt-to-Equity | 26.1 |
| Current Ratio | 0.4 |
| Total Assets | $21M |
Price & Trading
| Last Close | $1.06 |
| 50-Day MA | $1.58 |
| 200-Day MA | $2.47 |
| Avg Volume | 57K |
| Beta | 0.3 |
|
52-Week Range
$0.73
| |
About ABVC BIOPHARMA, INC. (ABVC)
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ABVC BIOPHARMA, INC. (ABVC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ABVC BIOPHARMA, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ABVC BIOPHARMA, INC.'s debt ratio?
ABVC BIOPHARMA, INC.'s debt ratio is 7.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 32.2%.
What are ABVC BIOPHARMA, INC.'s key financial metrics?
ABVC BIOPHARMA, INC. has a market capitalization of $25M. Return on equity stands at -119.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.